The Motley Fool
18 Jun 2026, 05:30 UTC · 2h ago
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
18 Jun 2026, 05:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Moderna is nearing potential regulatory approval for its influenza vaccine, mRNA-1010, targeting the elderly population. — FDA approval of a new primary product line in a large addressable market typically drives significant share price appreciation.
+0.60Krystal Biotech is expanding the geographic reach of its FDA-approved gene therapy Vyjuvek into European and other international markets. — International expansion of a first-to-market drug creates a direct path for sustained revenue and earnings growth.
+0.50Moderna has a personalized cancer vaccine, mRNA-4157, currently in phase 2 and phase 3 clinical studies. — Positive data from late-stage oncology trials represents a high-upside catalyst for biotech valuations.
+0.40Continue reading
6 related stories
Search tags
Krystal Biotech has maintained a streak of 11 consecutive quarters of positive earnings per share. — Consistent profitability is a strong risk-mitigating signal for small-cap biotech companies.
+0.30Which stocks this story touches
Strong revenue and earnings growth driven by Vyjuvek and a positive 11-quarter earnings streak.
The company is making significant progress toward new approvals for vaccines and has a promising cancer vaccine pipeline.
Mentioned as one of three stocks that have significantly outperformed the broader market this year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
5h ago
